Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.
Acta Haematol. 2015;134(4):248-54. doi: 10.1159/000430835.
Acta Haematol. 2015.
PMID: 26159458
Clinical Trial.
Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, Vergílio B, Silveira RA, Oliveira-Duarte V, Lorand-Metze I, De Souza CA, Pagnano KB.
Ribeiro BF, et al.
Clinics (Sao Paulo). 2015 Aug;70(8):550-5. doi: 10.6061/clinics/2015(08)04.
Clinics (Sao Paulo). 2015.
PMID: 26247667
Free PMC article.
Item in Clipboard
Cite
Cite